Phase 4 N=45 Nebivolol, Lifestyle Modification and Arterial Stiffness
Hypertension
Primary: Beta-stiffness Index — -2.03; -1.87; -2.51 Arbitrary units
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=302 Evaluation of the Long-term Persistence of Immunity to Hepatitis B, in Adolescents Vaccinated in Infancy With Engerix™-B Kinder
Hepatitis B
Primary: Number of Subjects With Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations Equal to or Above the Cut Off Value. — 265 Participants
Phase 2 N=153 A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy.
Non-small-cell Lung Cancer
Primary: Response Assessment by Study Stratum - Per Investigator Assessment — 0; 6; 3; 7 Participants
Phase 1 N=91 A Study of Grazoprevir (MK-5172) in Hepatitis C-Infected Male Participants (MK-5172-004)
Hepatitis C
Primary: Number of Participants With Clinical and Laboratory Adverse Events (AEs) — 6; 3; 13; 4 Participants
N/A N=437 Reciprocating Medical Devices - a Study of a New Safety Device
Osteoarthritis · Rheumatoid Arthritis · Trauma
Primary: Pain Using VAS (Visual Analogue Pain Scale) — 5.2; 6.2 cm
Phase 2 N=368 Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003)
Hepatitis C, Chronic
Primary: Percentage of Participants Achieving Complete Early Viral Response (cEVR) — 94.4; 80.3; 85.3; 87.5 percentage of participants
N/A N=36 Validation of Safety and Efficacy for Night Shift Therapy
Obstructive Sleep Apnea
Primary: Percentage of Participants Who Completed the Study at 4 Weeks Without Adverse Events — 100 Percentage of participants
Phase 3 N=44 Study of Brexpiprazole as Adjunctive Treatment of Sleep Disturbances in Patients With Major Depressive Disorder
Sleep Disturbances
Primary: Changes From Baseline to Week 8 on Sleep Quality as Assessed by Polysomnographic Recorded (PSG) Parameters — -24.9; -19.7; -26.4; 49.0 minutes (min)
Phase 4 N=12 Study to Assess Eradication of Nasal Carriage of Staphylococcus Aureus (SA) With Mupirocin (Bactroban 2% Nasal Ointment)
Staphylococcal Infection
Primary: Apparent Eradication of Nasal Carriage of SA — 9 participants
N/A N=18 Observational Study of Citrate Based Dialysis in Pediatric Patients Receiving Hemodialysis
Complication of Dialysis
Primary: Dialyzer Clotting Rate — 6 percentage of total treatments
Phase 3 N=34 Pamidronate to Treat Osteogenesis Imperfecta in Children
Osteogenesis Imperfecta
Primary: Change in Bone Mineral Density in Response to Pamidronate — -3.54; -4.98 Z-score
Phase 3 N=1,156 Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension
Primary: Time From Randomization to the First Morbidity Event or Death (All Causes) up to 7 Days After the Last Study Drug Intake — 91.2; 81.7; 83.1; 70.6 Percentage of patients…
N/A N=40 The Family Cognitive Adaptation Training Manual: A Test of Effectiveness
Psychosis
Primary: Multnomah Community Ability Scale (MCAS) — 67.78; 74.63; 70.00; 74.38 units on a scale
Phase 2 N=2 Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer
Recurrent Non-small Cell Lung Cancer · Squamous Cell Lung Cancer
Primary: Maximum Tolerated Dose (MTD) of FGFR Inhibitor AZD4547 — NA mg
N/A N=97 Investigation of the Effectiveness of Sevoflurane Anaesthesia in Difficult to Intubate Egyptian Patients
Intubation; Difficult
Primary: Percentage of Participants With Successful Intubation (Clinical Success) — 96.9; 3.1 percentage of participants